
About MediSensonic
MediSensonic is a Healthcare company based in Wrocław (Poland) founded in 2018. MediSensonic is engaged in developing innovative medical diagnostic devices. It operates on a HealthTech model. MediSensonic has raised $3.17 million across 2 funding rounds from investors including Agencja Badań Medycznych. Its chief executive, as recorded, is Robert Gromada. MediSensonic offers products and services including Glucowave, MPVT (Microwave Pulp Vitality Tester), and Touchwave. Its focus areas include MedTech and Diagnostic Devices.
Company details
MediSensonic is focused on the development of cutting-edge medical and dental diagnostic devices. The company specializes in non-invasive technologies utilizing microwave and photo-optical techniques. Solutions are provided in key medical areas such as cardiology, diabetology, dentistry, and oncology. Products like Glucowave, MPVT, and Touchwave are designed to enable precise and rapid diagnoses. The company is recognized for its contributions to healthcare innovation through various awards.
- Headquarters Wrocław, Poland
- SectorsHealthcare
- Email••••••••
- Website medisensonic.com
- Social LinkedIn X
- Legal Name Medisensonic
- Annual Revenue$11.22 K (USD)4as on Dec 31, 2023
- Net Profit-$1.02 M (USD)-87as on Dec 31, 2023
- EBITDA-$1.03 M (USD)-85as on Dec 31, 2023
- Total Equity Funding$3.17M (USD)
in 2 rounds
- Latest Funding Round$2.4M (USD), Series D
Jan 2025
- Investors
Products & Services of MediSensonic
MediSensonic offers a comprehensive portfolio of products and services, including Glucowave, MPVT (Microwave Pulp Vitality Tester), and Touchwave.
Non-invasive glucose monitoring system for continuous blood sugar tracking.
Innovative microwave technology used for quick dental vitality testing.
Cuffless blood pressure monitoring system for continuous precise measurements.
Funding Insights of MediSensonic
MediSensonic has successfully raised a total of $3.17M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $2.4 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.17M
- Total Rounds 2
- Last Round Series D — $2.4M
- First Round $764,466
(Sep 2023)
- Investors Count 1
All 2 funding rounds of MediSensonic with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $2.4M | Series D | – | Abm | – |
| Sep 2023 | $764,466 | Series D | – | – | – |
1 investors in total: 1 institutional.
Investors in MediSensonic
MediSensonic has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Agencja Badań Medycznych.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical research is supported through funding and clinical trials. | abm.gov.pl | Warsaw, Poland |
Investor details for MediSensonic
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MediSensonic
1 people are tracked at MediSensonic (1 in leadership).
| Name | Role | Group |
|---|---|---|
Robert Gromada | CEO | Leadership |
Complete people profiles for MediSensonic
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MediSensonic
3 dated milestones of MediSensonic across 7 years, from founding to its latest funding, stage changes and deals.
- Founded MediSensonic is founded.
- Funding First funding round of $764K.
- Funding Latest funding round, Series D, of $2.4M.
Web traffic of MediSensonic
Websites that share an audience with MediSensonic (medisensonic.com).
Websites whose visitors overlap most with MediSensonic. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
irforum.pl | irforum.pl | 100% | #3,864,546 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medisensonic
Complete news archive for MediSensonic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MediSensonic
MediSensonic was founded in 2018 and raised its 1st funding round 5 years after it was founded.
MediSensonic is headquartered in Wrocław, Poland. It is registered at Wrocław, Lower Silesian Voivodeship, Poland.
Robert Gromada is the CEO of MediSensonic, as recorded in our data.
MediSensonic is a funded company, having raised a total of $3.17M across 2 funding rounds to date. The company's 1st funding round was a Series D of $764.47K, raised on Sep 2023.
Annual revenue of MediSensonic is $11.22K as on Dec 31, 2023.
MediSensonic is focused on the development of cutting-edge medical and dental diagnostic devices. The company specializes in non-invasive technologies utilizing microwave and photo-optical techniques. Solutions are provided in key medical areas such as cardiology, diabetology, dentistry, and oncology. Products like Glucowave, MPVT, and Touchwave are designed to enable precise and rapid diagnoses. The company is recognized for its contributions to healthcare innovation through various awards.
MediSensonic offers Glucowave, MPVT (Microwave Pulp Vitality Tester), and Touchwave.
MediSensonic has 1 investor. Key investors include Agencja Badań Medycznych.
MediSensonic operates through Medisensonic.
